Related Experiment Video

Updated: Jun 24, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.1K

The Impact of Permanent Pacemaker Implantation After TAVI on Mortality and Quality of Life: A POPular TAVI Substudy

P J A van Nuland1, J Halim2, D J van Ginkel3

  • 1Faculty of Health, Medicine and Life Sciences (FHML), University Maastricht, Maastricht, The Netherlands.

Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions
|January 29, 2025
PubMed
Abstract

Insights

Permanent pacemaker implantation (PPI) before or after transcatheter aortic valve implantation (TAVI) did not increase 1-year mortality. However, PPI before TAVI was linked to reduced physical quality of life.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiac Electrophysiology

Background:

  • Conduction disturbances are frequent after transcatheter aortic valve implantation (TAVI).
  • Permanent pacemaker implantation (PPI) is often required, but its impact on outcomes is debated.
  • This study investigates the effects of PPI timing on mortality and quality of life (QoL) post-TAVI.

Purpose of the Study:

  • To evaluate the impact of pre-TAVI or early post-TAVI PPI on 1-year mortality.
  • To assess the effect of PPI timing on health-related QoL during the first year after TAVI.

Main Methods:

  • Analysis of 978 patients from the POPular TAVI substudy.
  • Patients were grouped into: no PPI, PPI pre-TAVI, and PPI post-TAVI (within 30 days).
  • Mortality (all-cause and cardiac) and QoL (SF-12, EQ-5D-5L) were assessed at 1 year.

Main Results:

  • No significant difference in 1-year all-cause or cardiac death rates among the three groups.
  • Patients with PPI pre-TAVI reported lower physical component scores (PCS-12) compared to the no PPI group.
  • No significant QoL differences were observed between the PPI post-TAVI and no PPI groups.

Conclusions:

  • Permanent pacemaker implantation before or within 30 days after TAVI is not associated with increased 1-year mortality.
  • Pre-TAVI PPI may be associated with diminished physical quality of life post-procedure.
Keywords:
mortalitypermanent pacemaker implantationquality of lifetranscatheter aortic valve implantation

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K
Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels08:12

Fully Endoscopic Mitral Valve Repair with Percutaneous Cannulation of Groin Vessels

Published on: May 26, 2023

1.5K

Related Concept Videos

Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...